CASGEVY exagamglogene autotemcel Updated Aug 27
Watch quarterly CASGEVY revenue trends as the key value driver, Q3 2026 results (~Nov 2026) will show whether the 151% YoY growth rate is sustainable. The 19.4% short interest and 15.6 days to cover create squeeze potential on positive commercial surprises, but the lack of a near-term binary catalyst limits near-term trading conviction. The analyst mean target of $87.56 implies ~48% upside from current levels.
- CASGEVY is the first-ever FDA-approved CRISPR-based therapy, a landmark scientific and commercial asset with no direct CRISPR-based competitor
- Q2 2026 CASGEVY revenue reached $76M (+151% YoY), showing accelerating commercial adoption and growing patient uptake
- FDA label expansion to children aged 2+ opens a meaningful additional patient population
- CASGEVY is a complex, expensive cell therapy requiring bone marrow conditioning (chemotherapy), limiting patient willingness and physician adoption
- Vertex Pharmaceuticals books all CASGEVY revenue; CRISPR's ~40% profit share is netted as collaboration expense, reducing top-line transparency
- Competition from bluebird bio's Lyfgenia (approved gene therapy for SCD) and emerging alternatives could pressure market share